Anthos Therapeutics

• NCT05171049

  Phase 3, Terminated, 1,150 people, 28 Dec 2021

• Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT

  Consulting or advice, Grants or research support, 2 Sept 2026

• Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study

  Grants or research support, 28 Aug 2026

• Life's Essential 8: Optimizing Health in Older Adults

  Consulting or advice, Fees or honoraria, 23 Aug 2023

Sources: pubmed.ncbi.nlm.nih.gov